Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings?
On October 3, AEI’s Alex Brill and Kyle Pomerleau hosted a panel of experts to discuss the tax treatment of pass-through businesses and opportunities for reform.
Three policy experts join Richard Rubin of The Wall Street Journal to examine the current iteration of the Build Back Better Act.
Alex Brill was one of the panelists discussing his “commitment to expand biosimilar use in the United States and how physicians and government officials are looking to help.
Navigating the Evolving Opioid Crisis: A Conversation with House Committee on Energy and Commerce Republican Leader Greg Walden (R-OR)
On February 27, a panel of addiction experts and community leaders joined Rep. Greg Walden (R-OR) to discuss the nation’s ongoing efforts to curb opioid misuse and addiction.
As Brill sees it, there are 4 main categories of barriers to biosimilar uptake: reference product manufacturers, biosimilar manufacturers, policy, and education.